中国药理学通报Issue(9)：1233-1238,6.DOI:10.3969/j.issn.1001-1978.2015.09.011
多肽 AP25与多西他赛联合用药对人乳腺癌裸鼠移植瘤的抑制活性研究
Combination of polypeptide AP25 and docetaxel in the treatment of breast cancer
摘要
Abstract
Aim To evaluate whether the combination of polypeptide AP25 and docetaxel is more efficient in treating experimental breast cancer,than either reagent used alone,and to offer suggestions for clinical use. Methods An experimental breast carcinoma model was set up to investigate the anti-tumor effects of AP25 and docetaxel combination.The Q value was caluculat-ed by Guinness rules and the anti-tumor effects of the combination of polypeptide AP25 and docetaxel were e-valuated.Results The treatment by the combination of polypeptide AP25 and docetaxel showed a better tumor inhibition rate.The combination of AP25 20 mg ·kg -1 and docetaxel 10 mg·kg -1 significantly inhibi-ted the tumor growth with 0.85 <Q =1.01 <1.15, showing an additive effect while the combination of AP25 20 mg·kg -1 and docetaxel 5 mg·kg -1 signifi-cantly inhibited the tumor growth with Q =1.18 >1.15,showing a synergistic effect.Conclusions The combination of AP25 and docetaxel can significantly in-hibit the tumor growth with a synergistic effect and de-crease the dose of chemotherapy.关键词
AP25多西他赛/抗肿瘤多肽/乳腺癌/金氏公式/协同作用/联合给药Key words
AP25/docetaxel/anti-tumor peptide/breast cancer/Guinness rules/synergistic effect/com-bination therapy分类
医药卫生引用本文复制引用
王佳艺,何俊劲,郝静超,程昊冉,徐寒梅..多肽 AP25与多西他赛联合用药对人乳腺癌裸鼠移植瘤的抑制活性研究[J].中国药理学通报,2015,(9):1233-1238,6.基金项目
国家高技术研究发展计划（863计划）资助项目（No 2012AA020304）；国家科技部“重大新药创制”科技重大专项（No 2014ZX09508007-001，2012ZX09103301-004）；国家重点实验室培育计划 （）
